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Abstract Germline mutation of the FLCN gene causes
Birt–Hogg–Dube´ syndrome (BHD), a rare autosomal
dominant condition characterized by skin fibrofolliculo-
mas, lung cysts, spontaneous pneumothorax and renal
tumours. We identified a hitherto unreported pathogenic
FLCN frameshift deletion c.563delT (p.Phe188Serfs*35) in
a family of a 46-year-old woman presented with macro-
hematuria due to bilateral chromophobe renal carcinomas.
A heritable renal cancer was suspected due to the bilater-
ality of the tumour and as the father of this woman had
suffered from renal cancer. Initially, however, BHD was
overlooked by the medical team despite the highly sug-
gestive clinical presentation. We assume that BHD is
underdiagnosed, at least partially, due to low awareness of
this variable condition and to insufficient use of appropriate
genetic testing. Our study indicates that BHD and FLCN
testing should be routinely considered in patients with
positive family or personal history of renal tumours. In
addition, we demonstrate how patients and their families
can play a driving role in initiating genetic diagnosis,
presymptomatic testing of at-risk relatives, targeted disease
management, and genetic counselling of rare diseases such
as BHD.
Keywords Birt–Hogg–Dube´ syndrome  BHD 
Folliculin  FLCN  Haploinsufficiency  Inherited kidney
cancer
Introduction
Birt–Hogg–Dube´ syndrome (BHD, OMIM #135150) is a
rare autosomal dominant condition [1] characterized by
skin fibrofolliculomas [2], lung cysts with associated
spontaneous pneumothorax [3] and renal tumours [4]. The
disease is caused by germline mutation of the FLCN gene
at 17p11.2 (OMIM *607273), a tumour suppressor gene [5]
encoding folliculin [6], whose function remains largely
elusive despite intense research [7]. Since 2002, when the
first mutations in the FLCN gene were reported [6, 8], only
about 120 FLCN mutations have been published in BHD
patients (HGMD Professional version 2015.2 and LOVD
version May 2015). In this study, we report on a novel
germline FLCN frameshift deletion. Moreover, we
emphasize the importance of appropriate counselling and
genetic testing in patients with clinical features of BHD.
Patients and methods
Clinical data and medical history
A 46-year-old German woman (index patient) presented
with macrohematuria but no other complaint to her primary
physician. Since hematuria increased after a week, she was
referred to an urologist. Ultrasonography showed a mass in
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the right kidney. Subsequent computer tomography (CT) of
the abdomen, thorax and pelvis presented inhomogeneous
masses in both kidneys (6.6 9 5.4 cm right and
2.1 9 1.8 cm left) being highly suspicious of renal cancer
with no indication of metastases (Fig. 1a, b). Both masses
were removed by surgery. Pathology showed two mor-
phologically similar but not identical well differentiated
tumours, both signed out as eosinophilic variants of bilat-
eral chromophobe renal carcinomas (Fig. 1c, d). Tumour,
lymph node, and metastatic (TNM) stages were
pT2aN0M0, G1, R0 and pT1aN0M0, G1, R0 at the right
and left sides, respectively. In addition, thoracic CT
revealed several small lung cysts, especially in the basilar
region (Fig. 1e, g). Two years after the initial diagnosis of
renal cancer, the index patient started with the recom-
mended follow-up [4]. Magnetic resonance imaging (MRI)
of the abdomen and additional CT of the thorax did not
show any metastases, whereas the number and size of lung
cysts remained stable. So far, the index patient has not
developed any obvious fibrofolliculomas detectable in a
clinical examination by an experienced dermatologist.
As the father of the index patient had kidney surgery a
decade earlier, the husband of the index patient, an
advanced nurse practitioner in the oncology field, sus-
pected heritable renal cancer. After consulting the litera-
ture, he asked for a genetic counselling because of
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Fig. 1 Clinical manifestations
of BHD in the index patient (a–
e and g) and her father (f). a and
b Abdominal CT showing renal
tumors of the right a and left
b kidneys, as indicated by white
arrows. c, d Representative
histopathology of the right c and
left d renal tumors, revealing
eosinophilic variants of
chromophobe renal cell
carcinomas (940, H & E
staining). e, g Thoracic CT
showing lung cysts, as
exemplified by white arrows.
f Dome-shaped papules on the
face of the index patient’s father
classified as fibrofolliculomas
by skin biopsy
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suspected BHD. The presence of familial BHD was sup-
ported by the chromophobe histology of the bilateral
tumours and by lung cysts in the index patient as well as by
the fact that her father had developed multiple of the typ-
ical dome-shaped papules at his face and neck in the last
years, one of which was classified as fibrofolliculoma by
skin biopsy (Fig. 1f). Moreover, the father had kidney
surgery due to bilateral renal cancer but at the time of
surgery he was not aware of the underlying disease. The
pathology reports stated two clear cell renal cell carcino-
mas on the left side as well as multiple renal cell carci-
nomas and adenomas on the right side without specification
of their histological types. The father also had suffered
from skin basal cell carcinoma and at the age of 36 years
from rectal adenocarcinoma (not investigated for Lynch
syndrome). So far, no lung cysts have been detected in the
father and neither he nor the index patient has had a history
of pneumothorax. After appropriate genetic counselling,
the index patient as well as her father and her two adult
sons opted for the molecular genetic testing of the FLCN
gene and provided informed consent.
Genetic testing
Genomic DNA was isolated from peripheral blood leuko-
cytes. All coding exons (exons 4–14), and flanking intronic
sequences of the FLCN gene were amplified by polymerase
chain reaction and sequenced exon-by-exon using Sanger
sequencing under routine conditions (details are available
upon request). Detected sequence variant was verified by
repeated sequencing on newly amplified PCR products.
The control data set included publicly available whole
exome sequences (WES) of *60,000 unrelated individuals
collected by the Exome Aggregation Consortium (ExAC,
Cambridge, MA, http://exac.broadinstitute.org/gene/ENSG
00000154803, accessed May 2015).
Transcript analysis
Total RNA was extracted from PAXgene-stabilized
peripheral whole blood using the PAXgene blood RNA kit
(Qiagen, Hilden, Germany; www.qiagen.com) according to
the manufacturer’s instructions. Semi-quantitative
sequence analysis was performed as described elsewhere
[9]. Accordingly, reverse transcription (RT)-PCR was
performed to amplify complementary DNA (cDNA) frag-
ments using the Qiagen OneStep RT-PCR kit (Qiagen,
Hilden, Germany; www.qiagen.com) and cDNA-specific
primers flanking the mutated exon. RT-PCR products were
purified by ExoSAP-IT treatment (USB Corporation,
Cleveland, OH; www.usbweb.com) and subsequently
sequenced in both directions on an ABI PRISM 3100
Genetic Analyzer with POP-6 polymer using BigDye
terminator v1.1 (Applied Biosystems, Zug, Switzerland;
www.appliedbiosystems.com).
Results and discussion
In the index case, genetic testing revealed a heterozygous
1-bp deletion in exon 6 of the FLCN gene (NM_144997.5:
c.563delT, p.Phe188Serfs*35; Fig. 2), which has not been
previously reported and was not detected in *60,000
unrelated individuals (*120,000 alleles in the ExAC
database). This hitherto unreported deletion induces a fra-
meshift in the normal open reading frame of the FLCN
gene and the new reading frame of 35 codons ends in a
premature termination codon (PTC). Due to PTC, the
mutant transcript (mRNA) produced might be targeted for
nonsense-mediated mRNA decay (NMD), which leads to
the degradation of PTC-containing transcripts and hence
results in functional haploinsufficiency [9]. Indeed, in
PAXgene-stabilized blood samples semi-quantitative
sequencing confirmed not only the presence of PTC-con-
taining transcripts but also revealed reduced mutant tran-
script level in comparison to genomic DNA (gDNA with
relative mutant allele frequency of 50 %), suggesting
incomplete NMD (Fig. 2). Consequently, this novel fra-
meshift deletion leading to PTC and NMD is most proba-
bly the reason for the clinical manifestation of BHD in the
index patient and her father. In the affected tissues, how-
ever, the efficiency/extent of NMD remains to be
elucidated.
In addition, genetic testing revealed the FLCN mutation
c.563delT in the affected father and both still asymp-
tomatic sons of the index patient (note that the sons are
only 20 and 21 years old; Fig. 3). As the youngest patient
with BHD in whom renal tumour has been reported was
20 years of age [10], both sons will start with appropriate
tumour screening in the next future. The identification of
the familial FLCN mutation enables the (presymptomatic)
testing of other family members with a priori risk for BHD,
allowing for targeted disease management and genetic
counselling as well.
The husband of the index patient informed the family
(first-degree relatives and siblings of the index patient’s
father and their descendants) by an appropriate letter (ap-
proved by a medical geneticist) with details on the clinical
appearance, practical impact, and inheritance of BHD.
Moreover, the letter indicated that testing of the familial
FLCN mutation c.563delT is possible and that family
doctor may receive additional information but BHD
requires expert management in specialised genetic clinics.
Six months later, the patient’s father heard about lung
problems, which turned out to be a spontaneous pneu-
mothorax based on multiple lung cysts, in one of his 1st
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grade cousins (62-year-old female relative, Fig. 3). Thanks
to the letter, a potential relation to BHD was recognised
and the cousin is now in the decision process regarding
genetic testing.
Unlike renal tumours in patients with other inherited
kidney cancer syndromes [11], renal tumour pathology of
the index patient and her father differed and also varied to
some degree within these two individuals. This is consis-
tent with the finding of Pavlovich et al. [12], who found
that tumours of different histological types were detected in
the same patient (in four of ten cases) and that tumour
histology was not clearly concordant within affected
families.
The index patient’s father suffered from a rectal carci-
noma at a remarkably young age of 36 years. A possible
association between BHD and colon cancer has been
reported elsewhere [13, 14]. While Zbar et al. [15] only
found a statistically not significant higher risk for colonic
tumours in BHD patients, Nahorski et al. [16] hypothesised
that different mutations in FLCN might be associated with
differing risks of colorectal cancer since they found
a significantly higher risk of colorectal cancer in
patients with an exon 11 mononucleotide tract mutation
(c.1285dupC) compared to patients with a mutation in exon
6 (c.610_611delGCinsTA). These authors also suggested
that FLCN gene mutations might represent rather a pas-
senger than a driver mutation in colorectal cancer.
Skin basal cell carcinomas have been reported in BHD
patients [17]. So far, however, a causal relationship has not
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Fig. 2 Electropherograms showing the partial forward (50 ? 30)
sequence of the FLCN gene flanking the heterozygous deletion
c.563delT (arrow) in the index patient (Patient) compared with a
control individual (Control) at both genomic DNA (gDNA) and
transcript (cDNA) levels. Note sequence positions where the sequence
of the mutant (c.563delT) allele differs from the sequence of the wild-
type (Ref. Seq.) allele: The cDNA sequence of the mutant allele
resulted in reduced electropherogram peak heights in comparison
with the corresponding gDNA sequence, demonstrating incomplete
nonsense-mediated mRNA decay of the PTC-containing mutant
transcript (p.Phe188Serfs*35) in leukocytes
presymptomatic
(20 years old)
hematuria
renal carcinomas
lung cysts
renal carcinomas
rectal adenocarcinoma
fibrofolliculomas
presymptomatic
(21 years old)
I
II
III
1* 2
1 2*
1* 2*
3
lung cysts
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Fig. 3 Five-generation partial pedigree of the family of the index
patient. Males and females are represented by rectangles and circles,
respectively; individuals are numbered (1–3) per generation (I–V).
Asterisk indicates the confirmed heterozygous presence of the FLCN
deletion c.563delT (p.Phe188Serfs*35) in the index patient (IV.2), her
father (III.1), and both sons (V.1 and V.2). In her 1st cousin once
removed (III.3) as well as in her asymptomatic mother (III.2), brother
(IV.3), and husband (IV.1) no genetic testing was performed. Black
symbols indicate individuals with clinical manifestations as given
below the corresponding symbols
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been proved. The occurrence of basal cell carcinoma in the
index patient’s father can also be explained by his
heightened sun exposure as a carpenter. While he devel-
oped multiple fibrofolliculomas in the past 30 years
(Fig. 1f), his daughter (the index patient) has not shown
obvious sign of it. This observation can be explained by the
facts that phenotype varies within BHD families with the
same FLCN germline mutation and, although fibrofollicu-
lomas are common in FLCN mutation carriers ([50 %),
some of the BHD patients do not show cutaneous mani-
festations even beyond the age of 40 years [10, 18–20].
Thanks to sufficient information, the index patient’s
father was able to link the ‘‘lung problems’’ of his cousin to
BHD. Indeed, spontaneous pneumothorax and multiple
lung cysts in the 62-year-old cousin can be indicative of
BHD. If the cousin decides for molecular genetic testing of
the familial FLCN deletion and this mutation can be
detected, a further branch of the large family should be
informed about the risk of BHD and about the possibility of
targeted genetic testing. However, our experience with the
first round of information showed that some of the
informed relatives hesitated to seriously deal with the risk
to be affected by BHD. Despite the fact that the informa-
tion letter emphasised the advantages of screening for renal
cancer and restrained from some high-risk activities (such
as scuba diving due to risk for spontaneous pneumothorax),
informed relatives had a rather fatalistic view of the situ-
ation in the beginning, not least due to the fact that a dis-
ease-causing FLCN mutation as such cannot be corrected/
reversed.
BHD patients and individuals with risk for BHD may
have manifold questions and concerns [21]. For a helpful
answer, appropriate counselling and information on this
condition are required. As BHD is rare, however, there is
low awareness of this condition. Our study demonstrates
that even medical professionals need more awareness of
BHD as the medical team in charge failed to think of this
syndrome despite the highly suggestive clinical presenta-
tion. In fact, without the efforts of the patient’s husband the
diagnosis BHD would have been missed, with potential
medical consequences for the family. In addition to origi-
nal articles and reviews [22], the websites of GeneReviews
(www.ncbi.nlm.nih.gov/books/NBK1522), OMIM (omi-
m.org/entry/135150), Orphanet (www.orpha.net), and the
BHD foundation (www.bhdsyndrome.org) as well as
facebook users provide scientific and basic information not
only for medical professionals but also for BHD patients
and their relatives. The facebook or other online discussion
groups can answer individual questions timely.
Our study suggests that FLCN analysis should be part of
genetic testing in patients with suspected renal cancer,
especially in cases with syndromic features of BHD. We
believe that BHD has been underdiagnosed due to low
awareness of this variable condition and to insufficient use
of appropriate genetic testing. Considering that in the
ExAC database (exac.broadinstitute.org/gene/ENSG00000
154803) at least *20 most likely pathogenic FLCN
mutations (such as frameshift, stop, and splice site muta-
tions) are listed for *60,000 unrelated individuals, the
genetic predisposition for BHD might be more frequent (up
to *1/3000) than one could suspect from the fact that only
about 120 FLCN mutations have been described in the
HGMD and LOVD databases (cf. the prevalence of BHD is
estimated at 1/200,000 but the exact incidence is unknown;
www.orpha.net). As our study demonstrates, adequate
information gathering by patients and/or their relatives (in
our case by the husband of the index patient) can signifi-
cantly contribute to the successful, genetically confirmed
diagnosis of BHD.
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